Is it ethical to enroll a patient in a hepatitis C virus clinical trial when current standard of care is highly effective and safe?

Publisher： John Wiley & Sons Inc

E-ISSN： 2046-2484|6|5|120-121

ISSN： 2046-2484

Source： CLINICAL LIVER DISEASE (ELECTRONIC), Vol.6, Iss.5, 2015-11, pp. : 120-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What is the ethical responsibility of a provider when prescribing the new direct‐acting antiviral agents to patients with hepatitis C infection?

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 5, 2015-11 ,pp. : 117-119

John Wiley & Sons Inc

Access to resources Recommend Favorite

Screening for hepatitis B virus to prevent viral reactivation — who and when?

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 5, Iss. 2, 2015-02 ,pp. : 47-50

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effective epitope identification employing phylogenetic, mutational variability, sequence entropy, and correlated mutation analysis targeting NS5B protein of hepatitis C virus: from bioinformatics to therapeutics

By  

JOURNAL OF MOLECULAR RECOGNITION (ELECTRONIC), Vol. 28, Iss. 8, 2015-08 ,pp. : 492-505

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of patients with hepatitis C virus genotype 3: Where are we now?

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 6, Iss. 4, 2015-10 ,pp. : 79-81

John Wiley & Sons Inc

Access to resources Recommend Favorite

The new treatments for hepatitis C virus: An advanced practice provider's perspective

By  

CLINICAL LIVER DISEASE (ELECTRONIC), Vol. 4, Iss. 6, 2014-12 ,pp. : 153-155

John Wiley & Sons Inc

Access to resources Recommend Favorite